Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditionsTORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ...

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at Pinnacle Surgery Center in Austin, Texas, by ...

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked ...

What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...

A surgeon at St. Clair Hospital in Mt. Lebanon recently performed the first HIFU procedure for prostate cancer at St. Clair using advanced new ultrasound technology. This makes St. Clair the first ...

New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

Dr Veeru Kasivisvanathan (UCL Division of Surgery & Interventional Science) has been awarded the prestigious Society of ...

Down almost 70% from all-time highs, Profound Medical is an undervalued growth stock that offers significant upside potential ...

Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4 th- 5 th in Scottsdale, AZ. BTIG 13th Annual MedTech, Digital Health, Life ...

Market OverviewThe global transrectal ultrasound (TRUS) market is experiencing consistent expansion and is projected to grow at a compound annual growth rate of around 6% during the forecast period.

Everyone’s body is different, and what may work for one patient in surgery may not work for another. Doctors at Tampa General ...